During the last ten years Rivopharm has developed over 25 molecules and registered generic products in throughout Europe, directly and through its customers.

1961
Rivopharm was founded focusing its attention especially on the Swiss market, specializing in branded and generic pharmaceutical products.
1980
Activities shift to mass production and Rivopharm supplies Unicef and various International Humanitarian Organisations and Ministries of Health. Rivopharm invests in new equipement and technology to achieve quality, capability and efficiency.

1990
Rivopharm expands its business in several countries of the former Soviet Union.
1998
Refocus of activities to development and manufacture of generic products for European Markets.

2003
Significant investments are made to upgrade the production facilities to the latest cGMP standards. Rivopharm operates in a renovated plant, located in Manno, near Lugano.

2005
Change of ownership of the company: Rivopharm is in partnership with many of Europe’s leading generics companies allowing for more important investments.

2008
Increased production and packaging capacity by acquiring new equipments at all levels in the factory

2009

Large investment in modern technologies for Research and Development both in formulation and analytics

2010

Conclusion of several regulatory procedures at National and DCP level, including the first ever registration of Nicorandil tablets as generic product in some European countries

2011

First company to launch generic Nicorandil tablets in EU markets